Safety and Efficacy Evaluation of iAPA-DC/CTL Combined Gemcitabine Therapy on Advanced Pancreatic Cancer
The aim of this study is to evaluate the safety and efficacy of iAPA-DC/CTL combined gemcitabine therapy on advanced pancreatic cancer.
Carcinoma, Pancreatic Ductal
OTHER: iAPA-DC/CTL adoptive cellular immunotherapy|DRUG: Gemcitabine
6-month SR, 6 months survival rate, 6 months
PFS, progression-Free Survival, 6 months|OS, Over survival, 6 months|ORR, Objective Response Rate, 2 months|QOL, Quality of Life, 2 months
immunological markers, CD3, CD4,CD8,CD16,CD56,CD45,Treg(CD4,CD25, CD127low), IL-1B,IL-2R, IL-10,TNF-aï¼Œ, 2 months|Serum tumor biomarker, CA19-9,CEA, 2 months
The aim of this study is to evaluate the safety and efficacy of iAPA-DC/CTL combined gemcitabine therapy on advanced pancreatic cancer.